Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry–based de novo sequencing

20 Mar 2024

Abstract excerpt

Mucin 1 (MUC1) is a transmembrane mucin expressed at the apical surface of epithelial cells at mucosal surfaces. MUC1 has a barrier function against bacterial invasion and is well known for its aberrant expression and glycosylation in adenocarcinomas. The MUC1 extracellular domain contains a variable number of tandem repeats (VNTR) of 20 amino acids, which are heavily O -linked glycosylated. Monoclonal antibodies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Structure and Function
Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38508723
DOI: 10.26508/lsa.202302366

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry–based de novo sequencingPMID 38508723Read ↗

Generation and Characterization of Anti-MUC4 Monoclonal Antibodies Reactive with Normal and Cancer Cells in HumansSemantic proximity Read ↗

Characterization of Recombinant β Subunit of Human MUC4 Mucin (rMUC4β)Semantic proximity Read ↗

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG.Semantic proximity Read ↗

Ramifications of secreted mucin MUC5AC in malignant journey: a holistic viewSemantic proximity Read ↗

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive TumorsSemantic proximity Read ↗

GlycoVHH: Introducing N-glycans on the camelid VHH antibody scaffold - Optimal sites and use for macrophage deliverySemantic proximity Read ↗

Muc1 ImmunotherapySemantic proximity Read ↗

Affinity Maturation and Characterization of the Novel Monoclonal Antibody (mAb) PB-223 Targeting Cancer- Specific Core 2 O-GlycansSemantic proximity Read ↗

Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.Semantic proximity Read ↗

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.Semantic proximity Read ↗

Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical DiscoverySemantic proximity Read ↗

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.